# Syam Palakurthy

> Syam Palakurthy is the co-founder and CEO of SamaCare, a San Francisco healthcare-technology company that rips paper and fax out of the specialty-drug prior authorization process. After a Dartmouth engineering-and-economics degree and a stint at Bain (where he once asked to be staffed on anything but healthcare), he built a cloud platform that now connects 15,000+ providers across retina, oncology, neurology, and rheumatology, and has raised roughly $35 million to make getting a patient on therapy 'as simple as a credit card swipe.'

- **Role:** Co-Founder & CEO at SamaCare
- **Organizations:** SamaCare, Chronic Care Management LLC, ClearCost Health, Bain & Company
- **Nationality:** American
- **Education:** B.S. in Engineering modified with Economics, Dartmouth College
- **Known for:** Built SamaCare into a platform partnering with over 15,000 providers, Raised roughly $35 million in total funding across Series A and B, Platform delivers reported 84% improvement in time-to-approval and 24% reduction in script abandonment

## Career timeline

- **early career** — Internships at Target, EnerNOC, and Spandana Sphoorty Financial
- **post-Dartmouth** — Associate Consultant at Bain & Company
- **mid career** — Founded Chronic Care Management LLC, helping primary care practices offer lifestyle coaching for diabetes and hypertension
- **later** — Senior Director of Product at ClearCost Health
- **2018** — Co-founded SamaCare to streamline prior authorization for specialty practices
- **2022** — Closed $12M Series A
- **2024** — Closed oversubscribed $17M Series B led by Questa Capital

## Achievements

- Built SamaCare into a platform partnering with over 15,000 providers
- Raised roughly $35 million in total funding across Series A and B
- Platform delivers reported 84% improvement in time-to-approval and 24% reduction in script abandonment
- Serves retina, oncology, neurology, and rheumatology practices representing $20B+ in annual specialty drug spend

## Latest updates

- **2024-05** — SamaCare secured $17M oversubscribed Series B led by Questa Capital to scale its specialty drug prior authorization platform.

## Links

- Website: https://samacare.com
- LinkedIn: https://www.linkedin.com/in/syam-palakurthy/

---

Profile page: https://yespress.io/syam-palakurthy
Published by YesPress — https://yespress.io
Last updated: 2026-06-04